Unique ID issued by UMIN | UMIN000058230 |
---|---|
Receipt number | R000066574 |
Scientific Title | Retrospective Study on the Effect of Imeglimin in Patients with Type 2 Diabetes Mellitus Complicated by Metabolic Dysfunction-Associated Steatotic Liver Disease |
Date of disclosure of the study information | 2025/06/20 |
Last modified on | 2025/06/20 10:04:36 |
Retrospective study examining the impact of imeglimine on patients with type 2 diabetes mellitus complicated by MASLD.
Imeglimin in MASLD patients with type 2 diabetes
Retrospective Study on the Effect of Imeglimin in Patients with Type 2 Diabetes Mellitus Complicated by Metabolic Dysfunction-Associated Steatotic Liver Disease
IME-MASLD: Imeglimin's Effect in Type 2 Diabetes Patients with MASLD - A Retrospective Study
Japan |
metabolic dysfunction associated steatotic liver disease
type 2 diabetes
Medicine in general | Endocrinology and Metabolism |
Others
NO
To assess the clinical course of patients with type 2 diabetes mellitus complicated by MASLD who are on regular hospital attendance, with and without imeglimine, and to assess its impact on glucose tolerance and MASLD.
Efficacy
Changes in HbA1c with and without imeglimine use in type 2 diabetes patients with MASLD.
Glucose tolerance related (GA, blood glucose, urinary albumin-creatinine ratio, blood C-peptide), fatty liver MASLD related (BMI, AST, ALT, G-GTP, ALP, T-Bil, ALB, PT, Total Cholesterol, TG, HDL Cholesterol, LDL Cholesterol, BUN, Cr, eGFR, Plt, Fib4 index, type 4 collagen 7S, autotaxin, M2BPGi, APRI, VCTE from fibroscan, CAP, FAST Score values, AGE, various InBody Changes in laboratory values (body weight, muscle mass, body fat percentage, extracellular water ratio)
Observational
Not applicable |
Not applicable |
Male and Female
1) Patients with type 2 diabetes mellitus complicated by fatty liver/MASLD who attended an eligible medical institution during the period under study, with and without imeglimine use.
2) Patients for whom the required data collection items (see below) are recorded in the electronic medical record.
1) Patients for whom the required data items cannot be collected in the medical record
80
1st name | Kensaku |
Middle name | |
Last name | Fukunaga |
Kagawa University,
Department of Endocrinology and Metabolism, Faculty of Medicine,
761-0793
1750-1, Ikenobe, Miki-cho, Kita-gun
0878912230
fukunaga.kensaku@kagawa-u.ac.jp
1st name | kensaku |
Middle name | |
Last name | fukunaga |
Kagawa university
Department of Endocrinology and Metabolism
761-0793
1750-1, Ikenobe, Miki-cho, Kita-gun
0878912230
fukunaga.kensaku@kagawa-u.ac.jp
Kagawa university
Fukunaga
none
Self funding
Ethics Committee, Faculty of Medicine, Kagawa University
1750-1, Miki-cho
0878985111
chiken-m@kagawa-u.ac.jp
NO
--- Select One ---
2025 | Year | 06 | Month | 20 | Day |
Published
80
Completed
2024 | Year | 12 | Month | 20 | Day |
2024 | Year | 12 | Month | 20 | Day |
2024 | Year | 12 | Month | 20 | Day |
2024 | Year | 12 | Month | 25 | Day |
ver.3
2025 | Year | 06 | Month | 20 | Day |
2025 | Year | 06 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066574